

Yehuda Ringel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11341145/publications.pdf>

Version: 2024-02-01

58
papers

7,313
citations

126708

33
h-index

149479

56
g-index

62
all docs

62
docs citations

62
times ranked

9418
citing authors

#	ARTICLE	IF	CITATIONS
1	Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial. PLoS ONE, 2021, 16, e0246871.	1.1	21
2	Noninvasive imaging and quantification of bile salt hydrolase activity: From bacteria to humans. Science Advances, 2021, 7, .	4.7	25
3	Cannabinoid receptor 2 agonist promotes parameters implicated in mucosal healing in patients with inflammatory bowel disease. United European Gastroenterology Journal, 2020, 8, 271-283.	1.6	12
4	The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflammatory Bowel Diseases, 2020, 26, 1306-1314.	0.9	35
5	Medical cannabis for inflammatory bowel disease: real-life experience of mode of consumption and assessment of side-effects. European Journal of Gastroenterology and Hepatology, 2019, 31, 1376-1381.	0.8	28
6	Bloating in Irritable Bowel Syndrome Is Associated with Symptoms Severity, Psychological Factors, and Comorbidities. Digestive Diseases and Sciences, 2019, 64, 1288-1295.	1.1	14
7	Endoscopic findings and esophageal cancer incidence among Fanconi Anemia patients participating in an endoscopic surveillance program. Digestive and Liver Disease, 2019, 51, 242-246.	0.4	10
8	Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2018, 63, 1890-1899.	1.1	72
9	The Gut Microbiome in Irritable Bowel Syndrome and Other Functional Bowel Disorders. Gastroenterology Clinics of North America, 2017, 46, 91-101.	1.0	42
10	Editorial: Clinical Implications of Diagnosing Irritable Bowel Syndrome: Do All Roads Need to Lead to Rome?. American Journal of Gastroenterology, 2017, 112, 900-902.	0.2	0
11	Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Benefit of the Probiotic Bifidobacterium infantis 35624 in Non-Patients With Symptoms of Abdominal Discomfort and Bloating. American Journal of Gastroenterology, 2017, 112, 145-151.	0.2	18
12	High-sensitive C-Reactive Protein as a Marker for Inflammation in Irritable Bowel Syndrome. Journal of Clinical Gastroenterology, 2016, 50, 227-232.	1.1	34
13	Preface. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 1-2.	1.0	0
14	Response to Valeur et al. and Farmer et al.. American Journal of Gastroenterology, 2016, 111, 147-148.	0.2	0
15	Probiotics in functional bowel disorders. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 89-97.	1.0	25
16	Use of probiotics in prevention and treatment of patients with Clostridium difficile infection. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 111-118.	1.0	28
17	Molecular characterization of the intestinal microbiota in patients with and without abdominal bloating. American Journal of Physiology - Renal Physiology, 2016, 310, G417-G426.	1.6	38
18	Discordant temporal development of bacterial phyla and the emergence of core in the fecal microbiota of young children. ISME Journal, 2016, 10, 1002-1014.	4.4	104

#	ARTICLE	IF	CITATIONS
19	Recommendations for Probiotic Use—2015 Update. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, S69-S73.	1.1	104
20	The Intestinal Microbiota and Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, S56-S59.	1.1	46
21	High throughput sequencing reveals distinct microbial populations within the mucosal and luminal niches in healthy individuals. <i>Gut Microbes</i> , 2015, 6, 173-181.	4.3	164
22	Testing in Microbiome-Profiling Studies with MiRKAT, the Microbiome Regression-Based Kernel Association Test. <i>American Journal of Human Genetics</i> , 2015, 96, 797-807.	2.6	248
23	Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2015, 110, 1339-1346.	0.2	101
24	Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial. <i>Complementary Therapies in Medicine</i> , 2014, 22, 17-20.	1.3	32
25	Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 305, G529-G541.	1.6	93
26	The intestinal microbiome, probiotics and prebiotics in neurogastroenterology. <i>Gut Microbes</i> , 2013, 4, 17-27.	4.3	194
27	Intestinal Microbiota in Healthy U.S. Young Children and Adults—A High Throughput Microarray Analysis. <i>PLoS ONE</i> , 2013, 8, e64315.	1.1	196
28	Fecal Protease Activity Is Associated with Compositional Alterations in the Intestinal Microbiota. <i>PLoS ONE</i> , 2013, 8, e78017.	1.1	48
29	Prebiotics and the Health Benefits of Fiber: Current Regulatory Status, Future Research, and Goals. <i>Journal of Nutrition</i> , 2012, 142, 962-974.	1.3	158
30	Defining a Healthy Human Gut Microbiome: Current Concepts, Future Directions, and Clinical Applications. <i>Cell Host and Microbe</i> , 2012, 12, 611-622.	5.1	615
31	Burden of Gastrointestinal Disease in the United States: 2012 Update. <i>Gastroenterology</i> , 2012, 143, 1179-1187.e3.	0.6	1,725
32	Anti-Enteric Neuronal Antibodies and the Irritable Bowel Syndrome. <i>Journal of Neurogastroenterology and Motility</i> , 2012, 18, 78-85.	0.8	39
33	Using Probiotics in Gastrointestinal Disorders. <i>American Journal of Gastroenterology Supplements (Print)</i> , 2012, 1, 34-40.	0.7	59
34	Characterization of the Fecal Microbiota Using High-Throughput Sequencing Reveals a Stable Microbial Community during Storage. <i>PLoS ONE</i> , 2012, 7, e46953.	1.1	190
35	Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. <i>American Journal of Physiology - Renal Physiology</i> , 2011, 301, G799-G807.	1.6	246
36	Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation. <i>New England Journal of Medicine</i> , 2011, 364, 22-32.	13.9	880

#	ARTICLE	IF	CITATIONS
37	Probiotic Bacteria <i>Lactobacillus acidophilus</i> NCFM and <i>Bifidobacterium lactis</i> Bi-07 Versus Placebo for the Symptoms of Bloating in Patients With Functional Bowel Disorders. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, 518-525.	1.1	150
38	The Rationale and Clinical Effectiveness of Probiotics in Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, S145-S148.	1.1	40
39	Luminal and mucosal-associated intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. <i>Cut Pathogens</i> , 2010, 2, 19.	1.6	167
40	Prevalence, Characteristics, and Impact of Bloating Symptoms in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 68-72.	2.4	130
41	Alterations in the Intestinal Microbiota and Functional Bowel Symptoms. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2009, 19, 141-150.	0.6	61
42	Randomized Controlled Trial Shows Biofeedback to be Superior to Pelvic Floor Exercises for Fecal Incontinence. <i>Diseases of the Colon and Rectum</i> , 2009, 52, 1730-1737.	0.7	206
43	Effect of Abuse History on Pain Reports and Brain Responses to Aversive Visceral Stimulation: An fMRI Study. <i>Gastroenterology</i> , 2008, 134, 396-404.	0.6	141
44	Yogurt Containing the Probiotic Bacteria <i>Bifidobacterium Lactis</i> Bb12 and Prebiotic Inulin Significantly Improves Colonic Transit Time in Subjects with Functional Bowel Symptoms. <i>American Journal of Gastroenterology</i> , 2008, 103, S479.	0.2	3
45	Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. <i>Gut</i> , 2007, 56, 1202-1209.	6.1	154
46	New Directions in Brain Imaging Research in Functional Gastrointestinal Disorders. <i>Digestive Diseases</i> , 2006, 24, 278-285.	0.8	14
47	Regional brain activation in response to rectal distension in patients with irritable bowel syndrome and the effect of a history of abuse. <i>Digestive Diseases and Sciences</i> , 2003, 48, 1774-1781.	1.1	78
48	Association of anterior cingulate cortex (ACC) activation with psychosocial distress and pain reports. <i>Gastroenterology</i> , 2003, 124, A97.	0.6	8
49	Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. <i>Gastroenterology</i> , 2003, 124, 754-761.	0.6	179
50	Brain Research in Functional Gastrointestinal Disorders. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, S23-S25.	1.1	17
51	Irritable Bowel Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2002, 35, S7-S10.	1.1	26
52	Alterations in regional decreased cerebral blood flow in patients with irritable bowel syndrome-A PET imaging study. <i>Gastroenterology</i> , 2001, 120, A637.	0.6	1
53	Biofeedback treatment of fecal incontinence. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 728-736.	0.7	147
54	Irritable Bowel Syndrome. <i>Annual Review of Medicine</i> , 2001, 52, 319-338.	5.0	98

#	ARTICLE	IF	CITATIONS
55	Dysfunction of the motivational-affective pain system in patients with IBS: Pet brain imaging in response to rectal balloon distension. <i>Gastroenterology</i> , 2000, 118, A444.	0.6	5
56	Increased saturation of the fatty acids in the sn-2 position of phospholipids reduces cholesterol crystallization in model biles. <i>Lipids and Lipid Metabolism</i> , 1998, 1390, 293-300.	2.6	9
57	The effects of phospholipid molecular species on cholesterol crystallization in model biles: the influence of phospholipid head groups. <i>Journal of Hepatology</i> , 1998, 28, 1008-1014.	1.8	11
58	The effects of dietary phospholipids enriched with phosphatidylethanolamine on bile and red cell membrane lipids in humans. <i>Lipids</i> , 1996, 31, 295-303.	0.7	13